Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 14/20 | 0.66 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.63 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.63 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.63 |
| ▸ | GRK5 | P34947 | 1/20 | 0.57 |
| ▸ | CHEK2 | O96017 | 3/20 | 0.55 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.55 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.54 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.54 |
| ▸ | PAK4 | O96013 | 1/20 | 0.54 |
| ▸ | ABL1 | P00519 | 1/20 | 0.54 |
| ▸ | LCK | P06239 | 1/20 | 0.54 |
| ▸ | RET | P07949 | 1/20 | 0.54 |
| ▸ | MET | P08581 | 1/20 | 0.54 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.54 |
| ▸ | PIM1 | P11309 | 1/20 | 0.54 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.54 |
| ▸ | FLT1 | P17948 | 1/20 | 0.54 |
| ▸ | LTK | P29376 | 1/20 | 0.54 |
| ▸ | KDR | P35968 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1679474 | 0.95 | PRKD3 (0.70) | FYNPRKD3PRKD1PRKD2GRK5 | |
| SCHEMBL1679531 | 0.88 | PRKD3 (0.72) | FYNPRKD3PRKD1PRKD2GRK5 | |
| SCHEMBL1679095 | 0.85 | PRKD3 (0.69) | FYNPRKD3PRKD1PRKD2GRK5 | |
| SCHEMBL1679726 | 0.85 | PRKD3 (0.68) | FYNPRKD3PRKD1PRKD2GRK5 | |
| SCHEMBL1679652 | 0.84 | FYN (0.81) | FYNPRKD3PRKD1PRKD2ACVR1 | |
| SCHEMBL1679754 | 0.84 | PRKD3 (0.69) | FYNPRKD3PRKD1PRKD2GRK5 | |
| SCHEMBL1679053 | 0.82 | PRKD3 (0.70) | FYNPRKD3PRKD1PRKD2GRK5 | |
| SCHEMBL1679706 | 0.82 | PRKD3 (0.75) | FYNPRKD3PRKD1PRKD2CHEK2 | |
| SCHEMBL1679478 | 0.82 | PRKD3 (0.77) | FYNPRKD3PRKD1PRKD2CHEK2 | |
| SCHEMBL1679148 | 0.82 | PRKD3 (0.72) | FYNPRKD3PRKD1PRKD2GRK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110098325-A1 | PYRIDINE BENZAMIDES AND PYRAZINE BENZAMIDES USED AS PKD INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2011-04-28 | — | — | US | claimed |
| US-20110098325-A1 | PYRIDINE BENZAMIDES AND PYRAZINE BENZAMIDES USED AS PKD INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2011-04-28 | — | — | US | disclosed |
| US-20110098325-A1 | PYRIDINE BENZAMIDES AND PYRAZINE BENZAMIDES USED AS PKD INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2011-04-28 | — | — | US | disclosed |
| US-20110098325-A1 | PYRIDINE BENZAMIDES AND PYRAZINE BENZAMIDES USED AS PKD INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2011-04-28 | — | — | US | disclosed |
| WO-2008074997-A1 | PYRIDINE BENZAMIDES AND PYRAZINE BENZAMIDES USED AS PKD INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098325-A1 | PYRIDINE BENZAMIDES AND PYRAZINE BENZAMIDES USED AS PKD INHIBITORS | PKD2, PKD1, BAZ2B | FYN 1665/4885PRKD3 38/4885PRKD1 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.